GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CareDx Inc (NAS:CDNA) » Definitions » Return-on-Tangible-Asset

CareDx (CareDx) Return-on-Tangible-Asset : -118.79% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is CareDx Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. CareDx's annualized Net Income for the quarter that ended in Dec. 2023 was $-472.4 Mil. CareDx's average total tangible assets for the quarter that ended in Dec. 2023 was $397.7 Mil. Therefore, CareDx's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -118.79%.

The historical rank and industry rank for CareDx's Return-on-Tangible-Asset or its related term are showing as below:

CDNA' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -162.69   Med: -30.35   Max: 2.98
Current: -44.62

During the past 12 years, CareDx's highest Return-on-Tangible-Asset was 2.98%. The lowest was -162.69%. And the median was -30.35%.

CDNA's Return-on-Tangible-Asset is ranked worse than
72.27% of 238 companies
in the Medical Diagnostics & Research industry
Industry Median: -8.34 vs CDNA: -44.62

CareDx Return-on-Tangible-Asset Historical Data

The historical data trend for CareDx's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CareDx Return-on-Tangible-Asset Chart

CareDx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.19 -9.78 -7.86 -16.27 -45.13

CareDx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.84 -20.98 -22.82 -22.20 -118.79

Competitive Comparison of CareDx's Return-on-Tangible-Asset

For the Diagnostics & Research subindustry, CareDx's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CareDx's Return-on-Tangible-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where CareDx's Return-on-Tangible-Asset falls into.



CareDx Return-on-Tangible-Asset Calculation

CareDx's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-190.284/( (462.417+380.789)/ 2 )
=-190.284/421.603
=-45.13 %

CareDx's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-472.388/( (414.517+380.789)/ 2 )
=-472.388/397.653
=-118.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


CareDx  (NAS:CDNA) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


CareDx Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of CareDx's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


CareDx (CareDx) Business Description

Traded in Other Exchanges
Address
8000 Marina Boulevard, Brisbane, CA, USA, 94005
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its primary operations are in Brisbane, California; Omaha, Nebraska; Fremantle, Australia and Stockholm, Sweden.
Executives
Reginald Seeto officer: See Remarks C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Peter Maag director, officer: President and CEO CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Abraham Ronai officer: See Remarks C/O CAREDX, INC., 8000 MARINA BLVD, BRISBANE CA 94005
Grace Colon director C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Abhishek Jain officer: See Remarks C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Michael Goldberg director 3000 SAND HILL ROAD, BUILDING 3, SUITE 290, MENLO PARK CA 94025
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Ankur Dhingra officer: Chief Financial Officer C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Arthur A Torres director 87 BVENA VISTA TERRACE, SAN FRANCISCO CA 94117
Alexander L Johnson officer: Chief Business Officer C/O DIADEXUS, INC., 349 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Sasha King officer: Chief Commercial Officer C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
William A Hagstrom director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Ralph Snyderman director C/O SAIC, 10260 CAMPUS POINT DR M/S F3, SAN DIEGO CA 92121
Marcel Konrad officer: See Remarks C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080